GRAL Stock Summary and Trading Ideas (Grail | NASDAQ:GRAL)

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Grail trades on the NASDAQ stock market under the symbol GRAL.

As of August 27, 2026, GRAL stock price climbed to $83.03 with 613,407 million shares trading.

GRAL has a beta of 1.42, meaning it tends to be more sensitive to market movements. GRAL has a correlation of 0.03 to the broad based SPY ETF.

GRAL has a market cap of $3.71 billion. This is considered a Mid Cap stock.

Last quarter Grail reported $43 million in Revenue and -$2.56 earnings per share. This fell short of revenue expectation by $-146,400 and missed earnings estimates by -$.05.

The top ETF exchange traded funds that GRAL belongs to (by Net Assets): XBI, IWM, VTI, IWN, VXF.

GRAL has outperformed the market in the last year with a price return of +143.7% while the SPY ETF gained +20.6%. GRAL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.4% and +20.4%, respectively, while the SPY returned +2.9% and -0.2%, respectively.

GRAL support price is $75.52 and resistance is $83.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRAL shares will trade within this expected range on the day.